Page last updated: 2024-08-17

cytidine monophosphate and Ovarian Neoplasms

cytidine monophosphate has been researched along with Ovarian Neoplasms in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (33.33)	24.3611
2020's	2 (66.67)	2.80

Authors

Authors	Studies
Blagden, SP; Kapacee, ZA; Knox, JJ; Lamarca, A; McNamara, MG; Palmer, D; Valle, JW	1
Blagden, SP; Gabra, H; Ghazaly, E; Gnanaranjan, C; Harrison, DJ; Kazmi, F; McCracken, NW; Nicum, S; Roux, RL; Spiers, L; Sukumaran, A	1
Bré, J; Chan, TH; Harrison, DJ; Mullen, P; Reynolds, PA; Sarr, A; Um, IH	1

Reviews

1 review(s) available for cytidine monophosphate and Ovarian Neoplasms

Article	Year
NUC-1031, use of ProTide technology to circumvent gemcitabine resistance: current status in clinical trials. Medical oncology (Northwood, London, England), 2020, Jun-11, Volume: 37, Issue:7 Topics: Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cisplatin; Clinical Trials as Topic; Cytidine Monophosphate; Deoxycytidine; Drug Resistance, Neoplasm; Drug Synergism; Female; Gemcitabine; Humans; Ovarian Neoplasms; Pancreatic Neoplasms; Randomized Controlled Trials as Topic; Treatment Outcome	2020

Article

Year

NUC-1031, use of ProTide technology to circumvent gemcitabine resistance: current status in clinical trials.

Medical oncology (Northwood, London, England), 2020, Jun-11, Volume: 37, Issue:7

Topics: Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cisplatin; Clinical Trials as Topic; Cytidine Monophosphate; Deoxycytidine; Drug Resistance, Neoplasm; Drug Synergism; Female; Gemcitabine; Humans; Ovarian Neoplasms; Pancreatic Neoplasms; Randomized Controlled Trials as Topic; Treatment Outcome

2020

Trials

1 trial(s) available for cytidine monophosphate and Ovarian Neoplasms

Article	Year
A Phase Ib Open-Label, Dose-Escalation Study of NUC-1031 in Combination with Carboplatin for Recurrent Ovarian Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 2021, 06-01, Volume: 27, Issue:11 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cytidine Monophosphate; Disease-Free Survival; Drug Dosage Calculations; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Treatment Outcome	2021

Article

Year

A Phase Ib Open-Label, Dose-Escalation Study of NUC-1031 in Combination with Carboplatin for Recurrent Ovarian Cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research, 2021, 06-01, Volume: 27, Issue:11

Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cytidine Monophosphate; Disease-Free Survival; Drug Dosage Calculations; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Treatment Outcome

2021

Other Studies

1 other study(ies) available for cytidine monophosphate and Ovarian Neoplasms

Article	Year
Genome-scale CRISPR/Cas9 screen determines factors modulating sensitivity to ProTide NUC-1031. Scientific reports, 2019, 05-21, Volume: 9, Issue:1 Topics: Antineoplastic Agents; Biomarkers, Tumor; Clinical Trials, Phase I as Topic; CRISPR-Cas Systems; Cytidine Monophosphate; Deoxycytidine; Deoxycytidine Kinase; Drug Resistance, Neoplasm; Female; Gemcitabine; HEK293 Cells; Humans; Ovarian Neoplasms; Pancreatic Neoplasms	2019

Article

Year

Genome-scale CRISPR/Cas9 screen determines factors modulating sensitivity to ProTide NUC-1031.

Scientific reports, 2019, 05-21, Volume: 9, Issue:1

Topics: Antineoplastic Agents; Biomarkers, Tumor; Clinical Trials, Phase I as Topic; CRISPR-Cas Systems; Cytidine Monophosphate; Deoxycytidine; Deoxycytidine Kinase; Drug Resistance, Neoplasm; Female; Gemcitabine; HEK293 Cells; Humans; Ovarian Neoplasms; Pancreatic Neoplasms

2019